ZS Pharma, Inc. et al v. Ascent Pharmaceuticals Inc. et al
ZS Pharma, Inc. and AstraZeneca Pharmaceuticals LP |
Ascent Pharmaceuticals Inc. and Hetero Drugs Ltd. |
1:2022cv01099 |
August 22, 2022 |
US District Court for the District of Delaware |
Gregory B Williams |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 Patent Infringement |
None |
Docket Report
This docket was last retrieved on October 19, 2022. A more recent docket listing may be available from PACER.
Document Text |
---|
|
|
Filing 18 STIPULATION TO EXTEND TIME to Respond to complaint to November 2, 2022 - filed by Ascent Pharmaceuticals Inc.. (Hitch, Cortlan) |
Filing 17 STIPULATION and [Proposed] Order Regarding Case Coordination and Extension of Deadline for Case Schedule by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc., AstraZeneca Pharmaecuticals LP. (Joyce, Alexandra) |
Filing 16 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,406,662 . (Silver, Daniel) |
Filing 15 First AMENDED COMPLAINT for Patent Infringement against Ascent Pharmaceuticals Inc., Hetero Drugs Ltd.- filed by ZS Pharma, Inc., AstraZeneca Pharmaceuticals LP. (Attachments: #1 Exhibit A-M, #2 Exhibit N-Q)(Silver, Daniel) |
|
Pro Hac Vice Attorney James Y. Li for AstraZeneca Pharmaceuticals LP and ZS Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:22-cv-01055-GBW, 1:22-cv-01096-GBW, 1:22-cv-01099-GBW, 1:22-cv-01100-GBW, 1:22-cv-01101-GBW(mpb) |
Filing 13 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Ascent Pharmaceuticals Inc.. (Dorsney, Kenneth) |
Filing 12 ANSWER to #1 Complaint, by Ascent Pharmaceuticals Inc..(Dorsney, Kenneth) |
Case Reassigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb) |
Pro Hac Vice Attorney Hassen Sayeed and Daniel O'Boyle for AstraZeneca Pharmaceuticals LP and ZS Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Related Cases: 1:22-cv-01101-VAC, 1:22-cv-01055-VAC, 1:22-cv-01096-VAC and 1:22-cv-01100-VAC. (mkr) |
|
Filing 11 MOTION for Pro Hac Vice Appearance of Attorney Hassen Sayeed, Daniel O'Boyle, and James Li - filed by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc., AstraZeneca Pharmaecuticals LP. (Attachments: #1 Certifications for Hassen Sayeed, Daniel O'Boyle, and James Li)(Silver, Daniel) |
Filing 10 NOTICE of Appearance of Lisa B. Pensabene by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc., AstraZeneca Pharmaecuticals LP (Silver, Daniel) |
Filing 9 DECLARATION of Service for Ascent Pharmaceuticals Inc. by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc.. (Attachments: #1 Exhibit A-B)(Joyce, Alexandra) |
Filing 8 VAC Notice, Consent, Non-Consent, Magistrate Referral (etg) |
Filing 7 ORAL ORDER: This case has been assigned to the District of Delaware's Vacant Judgeship ("VAC"). Detailed information relating to VAC cases may be found in the Court's Announcement of March 3, 2022 and Standing Order No. 2022-VAC-1 (March 9, 2022), which are found on the Court's website. Consistent with the foregoing Announcement and Standing Order, IT IS HEREBY ORDERED that the parties shall file the "Notice of Consent or Absence of Consent to Proceed Before a United States Magistrate Judge," being docketed along with the instant order, no later than sixty (60) days after service of the Complaint on the first defendant that is served. IT IS FURTHER ORDERED that the Notice, Consent, and Referral forms re: U.S. Magistrate Judge jurisdiction, previously docketed in this case, are VACATED. Issued by the Clerk of Court on 8/24/2022. (etg) |
Case Assigned to Vacant Judgeship (2022). Please include initials of VAC after the case number on all documents filed. Associated Cases: 1:22-cv-01096-VAC, 1:22-cv-01099-VAC, 1:22-cv-01100-VAC, 1:22-cv-01101-VAC (rjb) |
Filing 6 Summons Issued as to Ascent Pharmaceuticals Inc. on 8/22/2022; Hetero Drugs Ltd. on 8/22/2022. (Attachments: #1 Summons Issued Hetero Drugs Ltd)(smg) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc. filed by AstraZeneca Pharmaceuticals LP, ZS Pharma, Inc. (smg) |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: #1 Patent/Trademark Report 2, #2 Patent/Trademark Report 3)(smg) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than July 18, 2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 11/18/2025. (smg) |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) |
Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Ascent Pharmaceuticals Inc., Hetero Drugs Ltd. ( Filing fee $ 402, receipt number ADEDC-3942066.) - filed by ZS Pharma, Inc., AstraZeneca Pharmaceuticals LP. (Attachments: #1 Exhibit A-L, #2 Civil Cover Sheet)(smg) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.